Evaluate Vantage, Jacob Plieth, June 3, 2021
177Lu-PSMA-617 significantly improves overall survival and radiographic progression-free survival for men with metastatic castration-resistant prostate cancer in Phase III VISION study.
Indeed, Memorial Sloan Kettering’s Dr Michael Morris, who presented the late-breaker at an embargoed press briefing last week, said studies were ongoing in earlier-stage prostate cancer; clinicaltrials.gov shows phase 3 trials in pre-chemo, and in virtually treatment-naive hormone-sensitive patients.
